Late Vertebral Metastasis in Long-Term Survivors of Breast, Prostate, and Renal Cell Cancer
- 1Department of Neurosurgery-CU Anschutz School of Medicine and UCHealth-University of Colorado Hospital, Aurora, CO 80045, USA
Abstract
Long-term survivors of hormone receptor-positive breast cancer, prostate adenocarcinoma, and renal cell carcinoma may develop metastatic disease years after treatment. Vertebral involvement can cause instability and neurologic injury, but first late vertebral recurrence is poorly measured because studies frequently combine vertebral and other skeletal events. This narrative review synthesizes selected recurrence cohorts, experimental studies, randomized trials, and professional guidance. It distinguishes first late distant recurrence, biochemical recurrence, and progression of established metastatic disease; examines proposed mechanisms of marrow persistence; and considers detection and management. Late systemic risk is established, particularly in estrogen receptor-positive breast cancer, but vertebral-specific incidence remains uncertain. Niche studies provide biological plausibility without demonstrating a uniquely vertebral dormancy process. MRI assesses local marrow and neural involvement, while tumor-appropriate PET/CT maps disease distribution; tracer biology influences detection. Relevant trials address different questions: spinal MRI screening in metastatic castration-resistant prostate cancer, treatment of identified high-risk bone lesions, or metastasis-directed therapy in oligorecurrent disease. None establishes scheduled spine MRI for asymptomatic disease-free survivors. Concerning symptoms and tumor-specific recurrence signals warrant timely diagnostic evaluation. Identified lesions require assessment of neurologic compression, oncologic options, mechanical stability, and systemic status. Prospective cohorts and intervention studies should measure vertebral-specific events, function, quality of life, and downstream harms before risk-defined screening is recommended.
Related
- Fracture and Vertebral Augmentation Utilization Following Androgen Deprivation Therapy in Men With Prostate Cancer: A Propensity Score–matched Cohort Study
- Establishment and characterization of LNCaP-TR-BoM, a bone metastasis-derived prostate cancer cell line with an intermediate AR-attenuated phenotype
- Human bone marrow adipocytes drive prostate cancer bone metastasis progression via lipid-mediated induction of Angiopoietinlike 4
- Proteomic Characterization of Prostate Cancer Bone Metastasis Subtypes Defines Progressive Remodeling States of the Bone-Tumor Microenvironment
- A Case of Synchronous Subcarinal Lymph Node Metastasis from Double Primary Cancers with Small Cell Lung Cancer and Prostate Cancer
BibTeX
@article{berrycandelario2026late,
title = {{Late Vertebral Metastasis in Long-Term Survivors of Breast, Prostate, and Renal Cell Cancer}},
author = {John Berry-Candelario},
journal = {Cancers},
year = {2026},
month = nov,
doi = {10.3390/cancers18213543},
url = {https://www.mdpi.com/2072-6694/18/21/3543},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Late Vertebral Metastasis in Long-Term Survivors of Breast, Prostate, and Renal Cell Cancer
AU - John Berry-Candelario
PY - 2026
DA - 2026/11/04
JO - Cancers
DO - 10.3390/cancers18213543
UR - https://www.mdpi.com/2072-6694/18/21/3543
AB - Long-term survivors of hormone receptor-positive breast cancer, prostate adenocarcinoma, and renal cell carcinoma may develop metastatic disease years after treatment. Vertebral involvement can cause instability and neurologic injury, but first late vertebral recurrence is poorly measured because studies frequently combine vertebral and other skeletal events. This narrative review synthesizes selected recurrence cohorts, experimental studies, randomized trials, and professional guidance. It distinguishes first late distant recurrence, biochemical recurrence, and progression of established metastatic disease; examines proposed mechanisms of marrow persistence; and considers detection and management. Late systemic risk is established, particularly in estrogen receptor-positive breast cancer, but vertebral-specific incidence remains uncertain. Niche studies provide biological plausibility without demonstrating a uniquely vertebral dormancy process. MRI assesses local marrow and neural involvement, while tumor-appropriate PET/CT maps disease distribution; tracer biology influences detection. Relevant trials address different questions: spinal MRI screening in metastatic castration-resistant prostate cancer, treatment of identified high-risk bone lesions, or metastasis-directed therapy in oligorecurrent disease. None establishes scheduled spine MRI for asymptomatic disease-free survivors. Concerning symptoms and tumor-specific recurrence signals warrant timely diagnostic evaluation. Identified lesions require assessment of neurologic compression, oncologic options, mechanical stability, and systemic status. Prospective cohorts and intervention studies should measure vertebral-specific events, function, quality of life, and downstream harms before risk-defined screening is recommended.
SN - 2072-6694
ER -